Q4 seasonality and anti-infective dependency
Q4 historically weak due to seasonality and high anti-infective exposure, which could pressure margins.
medium · management_commentaryAlkem Laboratories Limited — Q3 FY24
Alkem reported a strong Q3 FY24 with 9% YoY revenue growth and 160bps EBITDA margin expansion to 21.3%, driven by lower API costs and favorable mix shift toward higher-margin RO...
bullish
high
Financial stats pending filing verification
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
US biosimilar facility execution risk
Analyst questioned rationale for US facility given past St. Louis closure and competitive biosimilar landscape; management acknowledged learnings but remains confident.
medium · analyst_questionRed Sea freight cost impact
Rising freight costs due to Red Sea disruptions could impact export margins; management sees manageable impact unless spike worsens.
low · analyst_questionTax rate normalization post-FY26
Tax holidays for Sikkim facility end in FY26, potentially raising effective tax rate from 10-12% to 20-25%.
medium · management_commentary